Loading
PASP / SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) · Phase 1 Trial
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for a Phase 1 interventional study evaluating sacubitril-valsartan's effect on estimated pulmonary artery systolic pressure in heart failure with reduced ejection fraction. Recruitment has been completed, but no results have been posted in this registry entry.
Phase 1, Interventional, Non Randomized, Parallel, Open label, Treatment purpose. PASP; age from 18 Years. Intervention: HFrEF patients on Sacubitril-Valsartan dose 24/26; HFrEF patients on Sacubitril-Valsartan dose 49/51. n = 59. 1 site: Egypt.
This is a registry record for a Phase 1 interventional study evaluating sacubitril-valsartan's effect on estimated pulmonary artery systolic pressure in heart failure with reduced ejection fraction. Recruitment has been completed, but no results have been posted in this registry entry.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
No clinical impact can be assessed from this registry record, as results are not posted. Clinicians should await publication of trial outcomes before considering implications for practice.
Phase 1 interventional study with completed enrollment but no results posted; registry record only describes the planned design and primary outcome measure.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be assessed from this registry record, as results are not posted. Clinicians should await publication of trial outcomes before considering implications for practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07814482). This is a study registration, not published results. Lead sponsor: Aswan University. Recruitment status: COMPLETED. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 59 participants (ACTUAL). Conditions: PASP. Interventions: DRUG: SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®). Primary outcome measures: Effect of Sacubitril-Valsartan on ePASP on patients with HFrEF , 1 year. Brief summary: Evaluate effect of Sacubitril-Valsartan on estimated pulmonary artery systolic pressure in patient with reduced ejection fraction heart failure
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.